Patents by Inventor Hidekazu Sawada
Hidekazu Sawada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6906177Abstract: The present invention provides a novel protein and its use. The protein or its salt, the partial protein, its amide or ester, or salts, and DNA encoding the same can be employed for obtaining antibodies and antisera, constructing the expression system of the protein of the present invention, for constructing the assay system for the GABA transporter activity and screen medicament candidate compounds using the expression system, for making drug design based on the steric structure of GABA transporters, as agents for producing probes or PCR primers in gene diagnosis, for preparing transgenic animals or as pharmaceuticals for the prevention/treatment of genetic disorders.Type: GrantFiled: June 8, 2000Date of Patent: June 14, 2005Assignee: Takeda Chemical Industries, Ltd.Inventors: Hiroyuki Kimura, Junichi Sakamoto, Hidekazu Sawada
-
Publication number: 20040214271Abstract: It is intended to provide a process for efficiently producing a recombinant protein free from the N-terminal methionine. In culturing a host transformed by an expression vector for expressing a gene-modified protein, the dissolved oxygen concentration in the liquid culture medium is controlled to about 1 ppm or lower. Thus, the ratio of the expression of a recombinant protein free from the N-terminal methionine is elevated compared with the case wherein no such control is performed.Type: ApplicationFiled: January 27, 2003Publication date: October 28, 2004Inventor: Hidekazu Sawada
-
Patent number: 6723522Abstract: The present invention relates to a protein having a Na+—HCO3− cotransporter activity and a DNA encoding it. The present protein and the present DNA can be used as or for [1] obtaining an antibody and antiserum, [2] constructing an expression system for the present protein, [3] development of a system for measuring the activity of a Na+—HCO3− cotransporter and screening of a drug candidate compound using the same expression system, [4] performing drug design based on the steric structure of a Na+—HCO3− cotransporter protein, [5] a reagent for making a probe or a PCR primer in gene diagnosis, [6] making a transgenic animal, or [7] a composition for gene prevention and/or treatment.Type: GrantFiled: June 20, 2001Date of Patent: April 20, 2004Assignee: Takeda Chemical Industries, Ltd.Inventors: Hiroyuki Kimura, Tomohiro Kawamoto, Hidekazu Sawada
-
Patent number: 6268354Abstract: This invention is to provide a pharmaceutical composition for antagonizing CCR5 which comprises a compound of the formula: wherein R1 is an optionally substituted 5- to 6-membered ring; W is a divalent group of the formula: wherein the ring A is an optionally substituted 5- to 6-membered aromatic ring, X is an optionally substituted C, N or O atom, and the ring B is an optionally substituted 5- to 7-membered ring; Z is a chemical bond or a divalent group; R2 is (1) an optionally substituted amino group in which a nitrogen atom may form a quaternary ammonium, etc., or a salt thereof.Type: GrantFiled: September 13, 2000Date of Patent: July 31, 2001Assignee: Takeda Chemical Industries, Ltd.Inventors: Osamu Nishimura, Masanori Baba, Hidekazu Sawada, Naoyuki Kanzaki, Ken-ichi Kuroshima, Mitsuru Shiraishi, Yoshio Aramaki
-
Patent number: 6172061Abstract: This invention is to provide a pharmaceutical composition for antagonizing CCR5 which comprises a compound of the formula: wherein R1 is an optionally substituted 5- to 6-membered ring; W is a divalent group of the formula: wherein the ring A is an optionally substituted 5- to 6-membered aromatic ring, X is an optionally substituted C, N or O atom, and the ring B is an optionally substituted 5- to 7-membered ring; Z is a chemical bond or a divalent group; R2 is (1) an optionally substituted amino group in which a nitrogen atom may form a quaternary ammonium, etc., or a salt thereof.Type: GrantFiled: December 17, 1998Date of Patent: January 9, 2001Assignee: Takeda Chemical Industries, Ltd.Inventors: Osamu Nishimura, Masanori Baba, Hidekazu Sawada, Naoyuki Kanzaki, Ken-ichi Kuroshima, Mitsuru Shiraishi, Yoshio Aramaki
-
Patent number: 5677184Abstract: Disclosed are CHO cells which are capable of continued production of human LH-RH receptor proteins, or cell membrane fractions thereof; recombinant human LH-RH receptor proteins or partial peptides thereof; methods for screening compounds which have affinity for an LH-RH receptor by contacting the compound with the CHO cells or the cell membrane fractions thereof, or the recombinant human LH-RH receptor proteins or the partial peptides thereof; kits for screening them; the compounds which have affinity for the LH-RH receptor obtained by methods for the screening or kits for the screening; and pharmaceutical compositions containing the compound, thereby being able to early provide prophylactic or therapeutic compositions, for example, for prostate cancer, uterine cancer, breast cancer, a pituitary tumor, endometriosis, hysteromyoma or precocious puberty. They are also useful as a pregnancy controlling composition such as contraceptive or a menstrual cycle controlling composition.Type: GrantFiled: April 18, 1995Date of Patent: October 14, 1997Assignee: Takeda Chemical Industries, Ltd.Inventors: Haruo Onda, Shoichi Ohkubo, Shuji Hinuma, Hidekazu Sawada
-
Patent number: 5213980Abstract: Disclosed are (1) a hybridoma carrying a vector for expressing a fibroblast growth factor (FGF) protein gene; (2) a method for producing the hybridoma of (1) which comprises transforming a hybridoma with the vector for expressing the FGF protein gene; and (3) a method for producing a biologically active substance which comprises cultivating in a culture medium the hybridoma obtained by the method of (2) using a hybridoma producing a biologically active substance other than the FGF protein, producing the FGF protein and producing and accumulating the biologically active substance in a culture, and recovering the biologically active substance, whereby the biologically active substance can be efficiently produced and recovered using the serum-free medium, which is advantageous for industrial production and very useful for an improvement in the breeding of the hybridoma.Type: GrantFiled: May 29, 1991Date of Patent: May 25, 1993Assignee: Takeda Chemical Industries, Ltd.Inventors: Hidekazu Sawada, Keiji Iwamoto, Kazuaki Kitano
-
Patent number: 4480033Abstract: Yield of lankacidin antibiotics is enhanced by incorporating cyclodextrin into a culture medium where a microorganism capable of producing lankacidin is cultivated.Type: GrantFiled: April 6, 1983Date of Patent: October 30, 1984Assignee: Takeda Chemical Industries, Ltd.Inventors: Takashi Suzuki, Junya Okada, Hidekazu Sawada
-
Patent number: 4334022Abstract: A method for producing mildiomycin in a commercial quantity and at low cost by cultivating a mildiomycin-producing microorganism belonging to Actinomycetes in a culture medium containing an N-methyl compound in an amount of at least 3 mM to have mildiomycin elaborated and accumulated in the culture broth.Type: GrantFiled: June 16, 1980Date of Patent: June 8, 1982Assignee: Takeda Chemical Industries, Ltd.Inventors: Takashi Suzuki, Hidekazu Sawada, Tsunetomo Asai
-
Patent number: 4296107Abstract: A compound of the formula: ##STR1##wherein R is hydrogen, a halogen atom or a lower alkyl group, or an acid salt thereof, possesses a superior fungicidal and acaricidal activity suitable for plant uses.Type: GrantFiled: August 19, 1980Date of Patent: October 20, 1981Assignee: Takeda Chemical Industries, Ltd.Inventors: Takashi Suzuki, Hidekazu Sawada, Kazuyoshi Katamoto